Search Results
Article
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
April 01, 2017
Article
Psoriasis patients with psoriasis area and severity index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: Results from two phase 3 studies of secukinumab
March 07, 2017
Article
A review of patient-reported outcome labeling in the United States (2011-2015)
March 01, 2017